ClinicalTrials.gg
CompletedNCT00043186Updated Sep 18, 2013Results posted

Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

A Phase 2 interventional study of Placebo and Denosumab in Low Bone Mineral Density, sponsored by Amgen. Completed. Open to female participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2013-09-18.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
Up to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies testing denosumab in Bone Diseases, Metabolic — 1 open to participants now, 1 under way, none of them phase 3. Denosumab · Bone Diseases, Metabolic.

Enrollment
5th of 25
412 · median 100
Started
2002
the only one that year
Phase 2
3 of 25
none open now
Registered
1st of 25
by date
Lead sponsor
12 of 25
Amgen

Among the 25 studies testing denosumab in Bone Diseases, Metabolic, this one is the 5th largest by enrollment, is the only one that started in 2002, is one of 3 in phase 2, and was the 1st registered.

Bone Diseases, Metabolic

663 studies on the registry are indexed under Bone Diseases, Metabolic; 95 are open to participants now.

Browse Bone Diseases, Metabolic studies →

Open to participants now

1 of the 25 studies testing denosumab in Bone Diseases, Metabolic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.

This study: Up to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing denosumab in Bone Diseases, Metabolic, or all of them as a file.
02

Study summary

To determine the effect of denosumab treatment compared with placebo over 12 months on bone mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD. The clinical hypothesis is that denosumab subcutaneous injections administered every 3 or 6 months for 12 months will significantly increase lumbar spine bone mineral density and will be well tolerated.

03

Conditions studied

  • Low Bone Mineral Density

Keywords

  • bone loss
  • osteoporosis
04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women not more than 80 years of age on date of randomization
  • ≥ 1 year on date of randomization
  • ambulatory
  • if ≤ 60 years of age, or had or would require a bilateral oophorectomy, serum follicle stimulating hormone (FSH) > 50 mU/mL or serum estradiol \< 20 pg/mL
  • low BMD (BMD T-score ≤ -1.8 at any 1 of the following sites: lumbar spine, femoral neck, or total hip; BMD T-scores must not have been \< -4.0 at the lumbar spine or - 3.5 at the femoral neck or total hip)
  • before any study-specific procedure, including the screening dual X-ray absorptiometry (DXA) scan, gave for participation in the study.

Exclusion criteria

Exclusion Criteria

  • fluoride treatment for osteoporosis within the 2 years before the enrollment date
  • bisphosphonate use within the 12 months before the enrollment date
  • administration of the following medications within the 6 months before the enrollment date

    • tibolone
    • Parathyroid hormone (PTH) (or any derivative)
    • systemic glucocorticosteroids (> 5 mg oral prednisone equivalent per day for > 10 days)
    • inhaled (> 2000 μg per day for > 10 days)
    • anabolic steroids or testosterone
  • administration of the following medications within the 3 months before the enrollment date

    • systemic hormone replacement therapy
    • selective estrogen receptor modulators
    • calcitonin
    • calcitriol
  • current hyper- or hypothyroidism (allowed if stable on thyroid replacement therapy and thyroid-stimulating hormone was within the normal range)
  • current hyper- or hypoparathyroidism
  • albumin-adjusted serum calcium \< 8.5 mg/dL (\< 2.125 mol/L)
  • osteomalacia
  • rheumatoid arthritis
  • Paget's disease
  • within the 5 years before enrollment (except cervical carcinoma in situ or basal cell carcinoma, which were acceptable)
  • renal disease; ie, ≤ 35 mL/min
  • any bone disease, other than osteoporosis, which could interfere with the interpretation of the findings (eg, osteogenesis imperfecta or osteopetrosis)
  • malabsorption syndrome
  • weight, height, or girth that could preclude accurate DXA measurements
  • \< 2 lumbar vertebrae (L1 through L4) evaluable by DXA
  • recent long bone fracture (within 6 months)
  • osteoporotic-related fracture (ie, crush or wedge vertebral fracture or hip fracture) known or suspected to have occurred within 2 years of randomization
  • > 1 single, grade 1 vertebral fracture
  • currently enrolled in or had participated within the previous 30 days in other device or drug trial(s) (For some trials, this may have been allowed after discussion and written approval from Amgen.)
  • known sensitivity to mammalian-derived drug preparations (eg, Herceptin®)
  • any organic or psychiatric disorder, serum chemistry, or hematology that, in the opinion of the investigator, could have prevented the subject from completing the study or have interfered with the interpretation of the study results
  • self-reported alcohol or drug abuse within the previous 12 months
  • any disorder that compromised the ability to give truly for participation in the study
  • previous administration of denosumab
  • known sensitivity or to alendronate
  • known sensitivity or contraindication to tetracycline derivatives (subjects in the substudy only).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
412 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.

    Drug: Placebo

  • Experimental
    Denosumab 6 mg every 3 months

    Participants received denosumab 6 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.

    Drug: Denosumab

  • Experimental
    Denosumab 14 mg every 3 months

    Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.

    Drug: Denosumab

  • Experimental
    Denosumab 30 mg every 3 months

    Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.

    Drug: Denosumab

  • Experimental
    Denosumab 14 mg every 6 months

    Participants received denosumab 14 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.

    Drug: Denosumab

  • Experimental
    Denosumab 60 mg every 6 months

    Participants received denosumab 60 mg SC every 6 months until Month 42.

    Drug: Denosumab

  • Experimental
    Denosumab 100 mg every 6 months

    Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.

    Drug: Denosumab

  • Experimental
    Denosumab 210 mg every 6 months

    Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.

    Drug: Denosumab

  • Active comparator
    Alendronate 70 mg

    Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.

    Drug: Alendronate

Interventions

  • DrugPlacebo

    Placebo subcutaneous injection

  • Denosumab for subcutaneous injection

    Also known as: AMG 162, Prolia

  • Alendronate 70 mg tablets

    Also known as: Fosamax

06

What researchers measure

Primary outcomes

  1. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Serum CTX Percent Change From Baseline at Month 12

    Serum C-Telopeptide (CTX). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and Month 12

  2. Urine NTX/Creatinine Percent Change From Baseline at Month 12

    Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and Month 12

  3. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Alendronate Arm

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and Month 12

  4. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 24 months

  5. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 36 months

  6. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 42 months

  7. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 48 months

  8. Serum CTX Percent Change From Baseline at Month 24

    Serum C-Telopeptide (CTX). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 24 months

  9. Serum CTX Percent Change From Baseline at Month 36

    Serum C-Telopeptide (CTX). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 36 months

  10. Serum CTX Percent Change From Baseline at Month 42

    Serum C-Telopeptide (CTX). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 42 months

  11. Serum CTX Percent Change From Baseline at Month 48

    Serum C-Telopeptide (CTX). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 48 months

  12. Urine NTX/Creatinine Percent Change From Baseline at Month 24

    Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 24 months

  13. Urine NTX/Creatinine Percent Change From Baseline at Month 36

    Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 36 months

  14. Urine NTX/Creatinine Percent Change From Baseline at Month 42

    Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 42 months

  15. Urine NTX/Creatinine Percent Change From Baseline at Month 48

    Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 48 months

  16. Total Hip Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 12 months

  17. Total Hip Bone Mineral Density Percent Change From Baseline at Month 24

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 24 months

  18. Total Hip Bone Mineral Density Percent Change From Baseline at Month 36

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 36 months

  19. Total Hip Bone Mineral Density Percent Change From Baseline at Month 42

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 42 months

  20. Total Hip Bone Mineral Density Percent Change From Baseline at Month 48

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 48 months

  21. Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 12 months

  22. Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 24 months

  23. Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 36 months

  24. Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 42 months

  25. Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 48 months

  26. Total Body Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 12 months

  27. Total Body Bone Mineral Density Percent Change From Baseline at Month 24

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 24 months

  28. Total Body Bone Mineral Density Percent Change From Baseline at Month 36

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 36 months

  29. Total Body Bone Mineral Density Percent Change From Baseline at Month 42

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 42 months

  30. Total Body Bone Mineral Density Percent Change From Baseline at Month 48

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 48 months

  31. Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12

    Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 12 months

  32. Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24

    Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 24 months

  33. Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36

    Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 36 months

  34. Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42

    Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 42 months

  35. Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48

    Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline and 48 months

07

Results

Posted Jul 28, 2010

Participant flow

First Subject Enrolled: 11-May-2002 Last Subject Enrolled: 30-Apr-2003

Participant flow — Overall Study
MilestonePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Started464444415447424747
Completed292924193639253130
Not completed17152022188171617
Withdrew: Physician decision003010011
Withdrew: Adverse event222321213
Withdrew: Withdrawal by subject118111314612910
Withdrew: Death001000200
Withdrew: Disease progression100300040
Withdrew: Ineligibility determined000000001
Withdrew: Lost to follow-up351111112
Withdrew: Noncompliance001100000
Withdrew: Other001100000

Outcome measures

PrimaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · Percent change
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6M
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms-0.81 ± 0.484.41 ± 0.504.71 ± 0.506.69 ± 0.543.03 ± 0.434.55 ± 0.475.52 ± 0.495.07 ± 0.47
Statistical analysis
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 5.87 · 95% CI 4.59 to 7.16
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 6.33 · 95% CI 5.01 to 7.65
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 5.35 · 95% CI 4.07 to 6.64
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 3.84 · 95% CI 2.60 to 5.07
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 7.50 · 95% CI 6.13 to 8.87
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 5.52 · 95% CI 4.19 to 6.85
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 5.21 · 95% CI 3.88 to 6.55
SecondarySerum CTX Percent Change From Baseline at Month 12

Serum C-Telopeptide (CTX). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and Month 12
Reported as:
Median · Percent change
Serum CTX Percent Change From Baseline at Month 12
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Serum CTX Percent Change From Baseline at Month 12-4.699 (-20.74 to 28.3)-61.366 (-74.42 to -41.92)-77.989 (-87.02 to -55.37)-87.238 (-90.53 to -71.25)-12.054 (-38.48 to 10.69)-70.757 (-81.47 to -55.78)-78.617 (-85.85 to -60.95)-84.107 (-90.70 to -77.85)-72.603 (-81.72 to -59.55)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.166
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryUrine NTX/Creatinine Percent Change From Baseline at Month 12

Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and Month 12
Reported as:
Median · Percent change
Urine NTX/Creatinine Percent Change From Baseline at Month 12
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Urine NTX/Creatinine Percent Change From Baseline at Month 1224.300 (-23.06 to 39.84)-40.018 (-49.76 to -6.38)-54.688 (-66.80 to -23.33)-60.652 (-73.16 to -46.40)-2.027 (-20.30 to 10.84)-36.523 (-54.67 to -16.06)-51.256 (-67.31 to -22.17)-58.502 (-70.55 to -29.84)-45.409 (-59.96 to -22.74)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.020
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Alendronate Arm

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · Percent change
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Alendronate Arm
Percent changeAlendronate 70 mg
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Alendronate Arm4.59 ± 0.45
SecondaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 24 months
Reported as:
Least squares mean · Percent change
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24-1.25 ± 0.687.42 ± 0.697.21 ± 0.688.83 ± 0.763.94 ± 0.607.19 ± 0.627.31 ± 0.677.86 ± 0.656.09 ± 0.63
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = <0.001 · Mean difference (final values): 7.34 · 95% CI 5.56 to 9.12
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 9.11 · 95% CI 7.31 to 10.91
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 8.56 · 95% CI 6.71 to 10.41
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 8.44 · 95% CI 6.69 to 10.19
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 5.19 · 95% CI 3.43 to 6.94
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 10.08 · 95% CI 8.14 to 12.01
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 8.46 · 95% CI 6.62 to 10.30
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 8.66 · 95% CI 6.80 to 10.53
SecondaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 36 months
Reported as:
Least squares mean · Percent change
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36-1.80 ± 0.828.57 ± 0.809.17 ± 0.891.94 ± 0.947.99 ± 0.729.04 ± 0.7410.63 ± 0.820.85 ± 0.724.70 ± 0.78
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = <0.001 · Mean difference (final values): 6.50 · 95% CI 4.32 to 8.67
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = 0.013 · Mean difference (final values): 2.65 · 95% CI 0.55 to 4.75
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 12.43 · 95% CI 10.19 to 14.68
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 10.84 · 95% CI 8.74 to 12.94
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 9.79 · 95% CI 7.69 to 11.89
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 3.74 · 95% CI 1.37 to 6.12
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 10.97 · 95% CI 8.63 to 13.32
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 10.37 · 95% CI 8.16 to 12.59
SecondaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 42 months
Reported as:
Least squares mean · Percent change
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 421.09 ± 1.707.21 ± 2.1310.04 ± 1.865.06 ± 2.139.46 ± 1.249.59 ± 1.409.99 ± 1.931.06 ± 1.806.51 ± 1.51
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = 0.02 · Mean difference (final values): 5.42 · 95% CI 0.89 to 9.95
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = 0.992 · Mean difference (final values): -0.03 · 95% CI -5.07 to 5.02
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = 0.004 · Mean difference (final values): 8.90 · 95% CI 3.72 to 14.09
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = 0.001 · Mean difference (final values): 8.50 · 95% CI 4.15 to 12.86
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = 0.001 · Mean difference (final values): 8.37 · 95% CI 4.11 to 12.63
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = 0.292 · Mean difference (final values): 3.98 · 95% CI -1.42 to 9.37
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = 0.004 · Mean difference (final values): 8.95 · 95% CI 3.94 to 13.96
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = 0.094 · Mean difference (final values): 6.12 · 95% CI 0.57 to 11.67
SecondaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 48 months
Reported as:
Least squares mean · Percent change
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48-2.39 ± 1.119.35 ± 1.099.93 ± 1.209.03 ± 1.3310.10 ± 0.9610.34 ± 0.9611.76 ± 1.132.50 ± 1.074.54 ± 1.06
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = <0.001 · Mean difference (final values): 6.93 · 95% CI 3.97 to 9.89
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 4.89 · 95% CI 1.92 to 7.85
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 14.15 · 95% CI 11.08 to 17.21
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 12.73 · 95% CI 9.94 to 15.52
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 12.49 · 95% CI 9.66 to 15.32
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 11.42 · 95% CI 8.12 to 14.73
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 12.32 · 95% CI 9.15 to 15.49
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 11.74 · 95% CI 8.72 to 14.76
SecondarySerum CTX Percent Change From Baseline at Month 24

Serum C-Telopeptide (CTX). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 24 months
Reported as:
Median · Percent change
Serum CTX Percent Change From Baseline at Month 24
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Serum CTX Percent Change From Baseline at Month 24-5.940 (-23.22 to 20.61)-50.687 (-73.73 to -27.21)-74.078 (-84.96 to -52.32)-83.985 (-89.66 to -74.02)-8.467 (-24.02 to 25.84)-68.437 (-81.80 to -44.39)-80.460 (-89.31 to -43.68)-85.680 (-90.94 to -78.32)-69.386 (-79.82 to -52.04)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.622
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
SecondarySerum CTX Percent Change From Baseline at Month 36

Serum C-Telopeptide (CTX). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 36 months
Reported as:
Median · Percent change
Serum CTX Percent Change From Baseline at Month 36
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Serum CTX Percent Change From Baseline at Month 36-16.577 (-28.96 to -0.29)-62.298 (-81.94 to -42.09)-53.643 (-82.23 to -34.04)56.286 (21.35 to 73.85)-57.500 (-75.77 to -23.56)-54.418 (-72.02 to -12.53)-45.057 (-81.69 to -11.29)72.135 (34.18 to 136.00)-33.982 (-56.86 to -21.93)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = 0.011
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.026
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.003
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
SecondarySerum CTX Percent Change From Baseline at Month 42

Serum C-Telopeptide (CTX). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 42 months
Reported as:
Median · Percent change
Serum CTX Percent Change From Baseline at Month 42
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Serum CTX Percent Change From Baseline at Month 42-16.279 (-31.66 to 18.31)-63.543 (-83.99 to -38.15)-40.827 (-85.17 to -13.72)-62.334 (-88.37 to -27.85)-46.408 (-80.65 to -32.46)-57.255 (-74.60 to -23.04)-56.377 (-77.35 to -20.98)33.999 (0.15 to 49.68)-46.743 (-58.94 to -26.14)
Statistical analysis
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.012
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.012
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = 0.002
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.012
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.012
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.004
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
SecondarySerum CTX Percent Change From Baseline at Month 48

Serum C-Telopeptide (CTX). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 48 months
Reported as:
Median · Percent change
Serum CTX Percent Change From Baseline at Month 48
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Serum CTX Percent Change From Baseline at Month 48-14.561 (-33.09 to 6.61)-40.016 (-80.76 to 0.11)-34.999 (-78.25 to -7.84)-52.656 (-78.86 to -5.25)-39.899 (-73.80 to -9.78)-51.494 (-78.57 to -14.62)-36.480 (-70.12 to -18.54)7.067 (-17.06 to 31.25)-43.724 (-56.28 to -14.07)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = 0.015
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.050
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.029
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.001
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.032
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.050
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.050
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.073
SecondaryUrine NTX/Creatinine Percent Change From Baseline at Month 24

Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 24 months
Reported as:
Median · Percent change
Urine NTX/Creatinine Percent Change From Baseline at Month 24
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Urine NTX/Creatinine Percent Change From Baseline at Month 2414.422 (-5.30 to 56.37)-19.699 (-51.71 to 1.61)-37.691 (-60.65 to -4.19)-49.907 (-68.26 to -20.43)2.134 (-15.60 to 45.10)-32.303 (-54.06 to 15.35)-37.001 (-72.15 to 11.74)-47.105 (-76.14 to -24.75)-44.482 (-59.46 to -8.98)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.001
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.409
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.001
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.003
SecondaryUrine NTX/Creatinine Percent Change From Baseline at Month 36

Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 36 months
Reported as:
Median · Percent change
Urine NTX/Creatinine Percent Change From Baseline at Month 36
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Urine NTX/Creatinine Percent Change From Baseline at Month 360.508 (-21.60 to 11.89)-33.294 (-56.03 to -3.63)-47.752 (-58.74 to -16.01)82.910 (32.79 to 108.70)-44.301 (-58.12 to -15.68)-36.874 (-57.37 to -5.32)-27.174 (-56.30 to 25.52)70.997 (24.80 to 125.90)-15.627 (-40.75 to 15.42)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = 0.011
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.077
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.002
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.002
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.002
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.005
SecondaryUrine NTX/Creatinine Percent Change From Baseline at Month 42

Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 42 months
Reported as:
Median · Percent change
Urine NTX/Creatinine Percent Change From Baseline at Month 42
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Urine NTX/Creatinine Percent Change From Baseline at Month 42-18.102 (-31.05 to 30.83)-40.741 (-60.82 to -12.95)-40.043 (-65.63 to -9.12)-58.893 (-67.49 to -14.26)-47.188 (-69.64 to -25.46)-39.269 (-64.25 to -4.97)-46.674 (-63.98 to -9.33)26.277 (-16.99 to 88.12)-33.102 (-53.10 to -19.07)
Statistical analysis
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.053
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.053
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = 0.022
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.032
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.053
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.053
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.020
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.053
SecondaryUrine NTX/Creatinine Percent Change From Baseline at Month 48

Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 48 months
Reported as:
Median · Percent change
Urine NTX/Creatinine Percent Change From Baseline at Month 48
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Urine NTX/Creatinine Percent Change From Baseline at Month 48-21.064 (-36.94 to 32.77)-23.311 (-62.33 to 11.43)-38.002 (-67.11 to -15.91)-50.864 (-80.48 to -9.49)-46.128 (-64.44 to -14.07)-40.375 (-70.06 to -0.46)-41.998 (-70.45 to -6.62)7.884 (-35.02 to 72.97)-32.198 (-59.36 to 6.68)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = 0.010
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.172
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.029
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.047
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.015
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.168
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.168
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.172
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 12 months
Reported as:
Least squares mean · Percent change
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12-0.56 ± 0.372.89 ± 0.382.45 ± 0.393.32 ± 0.421.94 ± 0.333.56 ± 0.362.53 ± 0.382.33 ± 0.362.11 ± 0.35
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = <0.001 · Mean difference (final values): 2.67 · 95% CI 1.70 to 3.64
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 2.90 · 95% CI 1.90 to 3.89
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 3.09 · 95% CI 2.07 to 4.11
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 4.12 · 95% CI 3.13 to 5.11
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 2.5 · 95% CI 1.55 to 3.46
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 3.89 · 95% CI 2.83 to 4.95
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 3.01 · 95% CI 1.99 to 4.04
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 3.46 · 95% CI 2.43 to 4.48
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 24

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 24 months
Reported as:
Least squares mean · Percent change
Total Hip Bone Mineral Density Percent Change From Baseline at Month 24
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Total Hip Bone Mineral Density Percent Change From Baseline at Month 24-1.92 ± 0.444.04 ± 0.453.55 ± 0.445.03 ± 0.502.62 ± 0.394.96 ± 0.403.67 ± 0.444.18 ± 0.433.27 ± 0.41
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = <0.001 · Mean difference (final values): 5.19 · 95% CI 4.04 to 6.34
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 6.10 · 95% CI 4.93 to 7.27
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 5.59 · 95% CI 4.40 to 6.78
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 6.89 · 95% CI 5.76 to 8.01
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 4.54 · 95% CI 3.41 to 5.67
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 6.95 · 95% CI 5.69 to 8.21
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 5.48 · 95% CI 4.29 to 6.67
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 5.97 · 95% CI 4.76 to 7.17
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 36

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 36 months
Reported as:
Least squares mean · Percent change
Total Hip Bone Mineral Density Percent Change From Baseline at Month 36
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Total Hip Bone Mineral Density Percent Change From Baseline at Month 36-2.84 ± 0.604.79 ± 0.584.41 ± 0.65-1.23 ± 0.684.31 ± 0.525.83 ± 0.544.33 ± 0.60-1.43 ± 0.530.93 ± 0.57
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = <0.001 · Mean difference (final values): 3.78 · 95% CI 2.19 to 5.36
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = 0.07 · Mean difference (final values): 1.41 · 95% CI -0.12 to 2.94
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 7.17 · 95% CI 5.54 to 8.80
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 8.67 · 95% CI 7.13 to 10.21
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 7.15 · 95% CI 5.62 to 8.69
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = 0.07 · Mean difference (final values): 1.61 · 95% CI -0.12 to 3.35
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 7.26 · 95% CI 5.56 to 8.95
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 7.63 · 95% CI 6.02 to 9.24
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 42

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 42 months
Reported as:
Least squares mean · Percent change
Total Hip Bone Mineral Density Percent Change From Baseline at Month 42
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Total Hip Bone Mineral Density Percent Change From Baseline at Month 42-1.96 ± 1.165.01 ± 1.433.98 ± 1.282.37 ± 1.464.54 ± 0.856.34 ± 0.984.70 ± 1.32-2.67 ± 1.232.98 ± 1.03
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = 0.002 · Mean difference (final values): 4.94 · 95% CI 1.86 to 8.02
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = 0.677 · Mean difference (final values): -0.71 · 95% CI -4.10 to 2.68
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = 0.001 · Mean difference (final values): 6.66 · 95% CI 3.14 to 10.18
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 8.29 · 95% CI 5.26 to 11.33
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 6.50 · 95% CI 3.59 to 9.41
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = 0.047 · Mean difference (final values): 4.33 · 95% CI 0.61 to 8.05
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = 0.003 · Mean difference (final values): 5.94 · 95% CI 2.53 to 9.36
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = 0.001 · Mean difference (final values): 6.97 · 95% CI 3.28 to 10.66
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 48

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 48 months
Reported as:
Least squares mean · Percent change
Total Hip Bone Mineral Density Percent Change From Baseline at Month 48
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Total Hip Bone Mineral Density Percent Change From Baseline at Month 48-3.52 ± 0.655.45 ± 0.634.03 ± 0.703.86 ± 0.774.82 ± 0.566.06 ± 0.564.99 ± 0.66-1.37 ± 0.621.17 ± 0.62
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = <0.001 · Mean difference (final values): 4.69 · 95% CI 2.97 to 6.41
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = 0.015 · Mean difference (final values): 2.16 · 95% CI 0.43 to 3.89
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 8.52 · 95% CI 6.74 to 10.30
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 9.58 · 95% CI 7.95 to 11.21
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 8.34 · 95% CI 6.70 to 9.99
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 7.38 · 95% CI 5.45 to 9.31
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 7.55 · 95% CI 5.72 to 9.38
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 8.97 · 95% CI 7.23 to 10.72
SecondaryDistal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 12 months
Reported as:
Least squares mean · Percent change
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12-1.97 ± 0.500.89 ± 0.520.40 ± 0.531.10 ± 0.550.94 ± 0.461.29 ± 0.481.07 ± 0.501.09 ± 0.51-0.53 ± 0.47
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = 0.033 · Mean difference (final values): 1.44 · 95% CI 0.11 to 2.76
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 3.06 · 95% CI 1.69 to 4.42
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 3.04 · 95% CI 1.68 to 4.40
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 3.26 · 95% CI 1.94 to 4.57
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 2.91 · 95% CI 1.60 to 4.21
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 3.07 · 95% CI 1.65 to 4.49
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 2.37 · 95% CI 0.99 to 3.76
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 2.86 · 95% CI 1.47 to 4.24
SecondaryDistal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 24 months
Reported as:
Least squares mean · Percent change
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24-2.78 ± 0.561.31 ± 0.570.62 ± 0.581.30 ± 0.632.48 ± 0.521.89 ± 0.511.48 ± 0.560.81 ± 0.56-0.78 ± 0.55
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = 0.009 · Mean difference (final values): 1.99 · 95% CI 0.49 to 3.49
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 3.58 · 95% CI 2.06 to 5.10
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 4.26 · 95% CI 2.73 to 5.78
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 4.09 · 95% CI 2.55 to 5.62
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 4.67 · 95% CI 3.23 to 6.11
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 5.26 · 95% CI 3.78 to 6.73
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 4.08 · 95% CI 2.48 to 5.68
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 3.39 · 95% CI 1.86 to 4.93
SecondaryDistal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 36 months
Reported as:
Least squares mean · Percent change
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36-3.64 ± 0.631.99 ± 0.601.06 ± 0.691.05 ± 0.712.08 ± 0.552.69 ± 0.551.92 ± 0.620.12 ± 0.57-0.95 ± 0.61
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = 0.002 · Mean difference (final values): 2.69 · 95% CI 1.01 to 4.38
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 3.77 · 95% CI 2.14 to 5.39
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 5.56 · 95% CI 3.87 to 7.26
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 6.33 · 95% CI 4.75 to 7.92
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 5.73 · 95% CI 4.12 to 7.33
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 4.70 · 95% CI 2.89 to 6.50
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 4.70 · 95% CI 2.92 to 6.49
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 5.63 · 95% CI 3.96 to 7.30
SecondaryDistal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 42 months
Reported as:
Least squares mean · Percent change
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42-6.59 ± 3.001.00 ± 3.260.82 ± 2.92-3.91 ± 3.391.29 ± 2.14-0.87 ± 2.930.02 ± 5.000.59 ± 2.52-3.32 ± 3.95
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = 0.496 · Mean difference (final values): 3.27 · 95% CI -7.16 to 13.7
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = 0.527 · Mean difference (final values): 6.60 · 95% CI -6.38 to 19.59
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = 0.503 · Mean difference (final values): 5.72 · 95% CI -2.90 to 14.33
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = 0.527 · Mean difference (final values): 2.68 · 95% CI -6.54 to 11.89
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = 0.503 · Mean difference (final values): 7.41 · 95% CI -2.19 to 17.01
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = 0.503 · Mean difference (final values): 7.59 · 95% CI -1.85 to 17.03
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = 0.503 · Mean difference (final values): 7.18 · 95% CI -2.45 to 16.81
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = 0.233 · Mean difference (final values): 7.88 · 95% CI 0.78 to 14.97
SecondaryDistal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 48 months
Reported as:
Least squares mean · Percent change
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48-4.67 ± 0.751.04 ± 0.731.42 ± 0.841.77 ± 0.911.74 ± 0.661.71 ± 0.651.37 ± 0.75-0.94 ± 0.74-2.67 ± 0.75
Statistical analysis
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 6.41 · 95% CI 4.48 to 8.34
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 6.44 · 95% CI 4.19 to 8.70
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 6.09 · 95% CI 3.91 to 8.26
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 5.72 · 95% CI 3.70 to 7.73
  • Placebo vs Alendronate 70 mg · ANCOVA · p = 0.054 · Mean difference (final values): 2.00 · 95% CI -0.04 to 4.04
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 3.74 · 95% CI 1.71 to 5.77
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 6.05 · 95% CI 4.00 to 8.10
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 6.39 · 95% CI 4.49 to 8.28
SecondaryTotal Body Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 12 months
Reported as:
Least squares mean · Percent change
Total Body Bone Mineral Density Percent Change From Baseline at Month 12
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Total Body Bone Mineral Density Percent Change From Baseline at Month 12-0.21 ± 0.461.82 ± 0.451.80 ± 0.462.74 ± 0.510.55 ± 0.412.51 ± 0.431.78 ± 0.462.08 ± 0.441.51 ± 0.44
Statistical analysis
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = 0.001 · Mean difference (final values): 2.30 · 95% CI 1.09 to 3.51
  • Placebo vs Alendronate 70 mg · ANCOVA · p = 0.005 · Mean difference (final values): 1.73 · 95% CI 0.52 to 2.93
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = 0.004 · Mean difference (final values): 2.00 · 95% CI 0.74 to 3.25
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 2.72 · 95% CI 1.54 to 3.91
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = 0.202 · Mean difference (final values): 0.77 · 95% CI -0.41 to 1.95
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 2.95 · 95% CI 1.65 to 4.26
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = 0.004 · Mean difference (final values): 2.02 · 95% CI 0.78 to 3.26
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = 0.004 · Mean difference (final values): 2.03 · 95% CI 0.80 to 3.27
SecondaryTotal Body Bone Mineral Density Percent Change From Baseline at Month 24

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 24 months
Reported as:
Least squares mean · Percent change
Total Body Bone Mineral Density Percent Change From Baseline at Month 24
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Total Body Bone Mineral Density Percent Change From Baseline at Month 24-1.64 ± 0.532.59 ± 0.542.91 ± 0.534.44 ± 0.620.89 ± 0.492.57 ± 0.493.00 ± 0.532.75 ± 0.531.50 ± 0.52
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = <0.001 · Mean difference (final values): 3.14 · 95% CI 1.71 to 4.56
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 4.40 · 95% CI 2.95 to 5.84
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 4.64 · 95% CI 3.19 to 6.09
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 4.22 · 95% CI 2.85 to 5.58
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 2.53 · 95% CI 1.13 to 3.94
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 6.09 · 95% CI 4.53 to 7.64
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 4.55 · 95% CI 3.12 to 5.98
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 4.23 · 95% CI 2.76 to 5.69
SecondaryTotal Body Bone Mineral Density Percent Change From Baseline at Month 36

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 36 months
Reported as:
Least squares mean · Percent change
Total Body Bone Mineral Density Percent Change From Baseline at Month 36
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Total Body Bone Mineral Density Percent Change From Baseline at Month 36-1.61 ± 0.943.14 ± 0.883.04 ± 0.982.34 ± 1.092.04 ± 0.832.80 ± 0.802.59 ± 0.94-0.29 ± 0.834.55 ± 0.94
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = <0.001 · Mean difference (final values): 6.16 · 95% CI 3.63 to 8.68
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = 0.275 · Mean difference (final values): 1.32 · 95% CI -1.06 to 3.7
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = 0.005 · Mean difference (final values): 4.20 · 95% CI 1.65 to 6.75
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = 0.002 · Mean difference (final values): 4.41 · 95% CI 2.07 to 6.75
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = 0.009 · Mean difference (final values): 3.65 · 95% CI 1.25 to 6.05
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = 0.009 · Mean difference (final values): 3.95 · 95% CI 1.22 to 6.68
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = 0.003 · Mean difference (final values): 4.65 · 95% CI 2.05 to 7.24
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = 0.001 · Mean difference (final values): 4.75 · 95% CI 2.28 to 7.22
SecondaryTotal Body Bone Mineral Density Percent Change From Baseline at Month 42

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 42 months
Reported as:
Least squares mean · Percent change
Total Body Bone Mineral Density Percent Change From Baseline at Month 42
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Total Body Bone Mineral Density Percent Change From Baseline at Month 421.61 ± 1.761.90 ± 3.714.05 ± 1.708.85 ± 3.073.72 ± 1.974.92 ± 1.833.79 ± 3.63-0.75 ± 1.502.85 ± 2.67
Statistical analysis
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = 0.949 · Mean difference (final values): 2.18 · 95% CI -8.73 to 13.10
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = 0.949 · Mean difference (final values): 3.30 · 95% CI -2.70 to 9.31
  • Placebo vs Alendronate 70 mg · ANCOVA · p = 0.709 · Mean difference (final values): 1.24 · 95% CI -6.81 to 9.29
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = 0.949 · Mean difference (final values): -2.36 · 95% CI -8.55 to 3.83
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = 0.949 · Mean difference (final values): 2.10 · 95% CI -4.51 to 8.72
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = 0.484 · Mean difference (final values): 7.23 · 95% CI -0.83 to 15.3
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = 0.949 · Mean difference (final values): 2.44 · 95% CI -3.77 to 8.66
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = 0.949 · Mean difference (final values): 0.29 · 95% CI -10.82 to 11.40
SecondaryTotal Body Bone Mineral Density Percent Change From Baseline at Month 48

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 48 months
Reported as:
Least squares mean · Percent change
Total Body Bone Mineral Density Percent Change From Baseline at Month 48
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Total Body Bone Mineral Density Percent Change From Baseline at Month 48-2.54 ± 0.993.68 ± 0.983.38 ± 1.073.76 ± 1.273.42 ± 0.863.43 ± 0.873.68 ± 1.03-0.29 ± 0.964.49 ± 1.00
Statistical analysis
  • Placebo vs Alendronate 70 mg · ANCOVA · p = <0.001 · Mean difference (final values): 7.02 · 95% CI 4.35 to 9.69
  • Placebo vs Denosumab 210 mg Q6M · ANCOVA · p = 0.092 · Mean difference (final values): 2.25 · 95% CI -0.37 to 4.87
  • Placebo vs Denosumab 100 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 6.22 · 95% CI 3.50 to 8.94
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 5.97 · 95% CI 3.51 to 8.43
  • Placebo vs Denosumab 14 mg Q6M · ANCOVA · p = <0.001 · Mean difference (final values): 5.96 · 95% CI 3.44 to 8.48
  • Placebo vs Denosumab 30 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 6.29 · 95% CI 3.25 to 9.34
  • Placebo vs Denosumab 14 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 5.91 · 95% CI 3.13 to 8.70
  • Placebo vs Denosumab 6 mg Q3M · ANCOVA · p = <0.001 · Mean difference (final values): 6.22 · 95% CI 3.58 to 8.87
SecondaryBone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12

Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 12 months
Reported as:
Median · Percent change
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12-4.609 (-26.46 to 30.31)-62.716 (-77.57 to -47.64)-60.098 (-76.61 to -41.34)-70.256 (-80.58 to -55.16)-39.474 (-64.97 to -13.73)-65.215 (-77.11 to -51.79)-61.979 (-74.25 to -50.61)-67.634 (-75.90 to -50.19)-61.059 (-69.89 to -46.08)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryBone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24

Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 24 months
Reported as:
Median · Percent change
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 2416.464 (-20.18 to 52.94)-41.225 (-65.61 to -22.04)-47.597 (-69.11 to -16.28)-57.905 (-66.41 to -22.36)-22.350 (-44.05 to 0.50)-43.448 (-62.70 to -18.28)-50.176 (-64.82 to -23.14)-48.833 (-71.34 to -27.38)-48.778 (-58.87 to -25.77)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.002
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryBone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36

Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 36 months
Reported as:
Median · Percent change
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 361.955 (-28.21 to 45.67)-39.012 (-66.11 to -12.10)-56.021 (-69.45 to -21.31)22.343 (-0.27 to 49.28)-47.500 (-63.87 to -32.19)-42.541 (-64.46 to -24.35)-47.418 (-57.70 to -22.78)61.747 (14.65 to 101.28)-8.209 (-40.84 to 7.80)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = 0.049
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.008
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.146
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.001
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryBone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42

Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 42 months
Reported as:
Median · Percent change
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 421.288 (-25.01 to 51.68)-40.182 (-65.62 to -11.21)-40.819 (-64.78 to -6.13)-52.684 (-67.62 to -34.69)-53.763 (-62.49 to -28.55)-44.892 (-62.36 to -25.45)-48.303 (-59.51 to -18.60)17.841 (4.18 to 82.99)-22.069 (-41.00 to 8.92)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = 0.061
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.058
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.001
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.003
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.003
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.002
SecondaryBone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48

Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline and 48 months
Reported as:
Median · Percent change
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48
Percent changePlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 4818.122 (-28.72 to 59.58)-34.727 (-56.34 to 3.83)-45.779 (-60.49 to 9.42)-47.770 (-60.61 to -30.76)-46.286 (-57.67 to -24.26)-34.361 (-59.73 to -9.38)-42.653 (-61.39 to -17.29)21.053 (8.00 to 54.55)-17.891 (-27.39 to 12.52)
Statistical analysis
  • Placebo vs Alendronate 70 mg · Wilcoxon (Mann-Whitney) · p = 0.142
  • Placebo vs Denosumab 210 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.218
  • Placebo vs Denosumab 100 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.003
  • Placebo vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = 0.010
  • Placebo vs Denosumab 14 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.001
  • Placebo vs Denosumab 30 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.010
  • Placebo vs Denosumab 14 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.020
  • Placebo vs Denosumab 6 mg Q3M · Wilcoxon (Mann-Whitney) · p = 0.020

Adverse events

Collected over 48 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—5/46 (10.9%)43/46 (93.5%)
Denosumab 6 mg Q3M—7/43 (16.3%)38/43 (88.4%)
Denosumab 14 mg Q3M—13/44 (29.5%)39/44 (88.6%)
Denosumab 30 mg Q3M—9/40 (22.5%)35/40 (87.5%)
Denosumab 14 mg Q6M—7/53 (13.2%)44/53 (83%)
Denosumab 60 mg Q6M—5/47 (10.6%)42/47 (89.4%)
Denosumab 100 mg Q6M—9/41 (22%)38/41 (92.7%)
Denosumab 210 mg Q6M—6/46 (13%)41/46 (89.1%)
Alendronate 70 mg—8/46 (17.4%)42/46 (91.3%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventPlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Angina pectorisCardiac disorders1/462/430/440/400/530/470/412/460/46
Breast cancer in situNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/460/432/440/400/530/470/410/460/46
Non-cardiac chest painGeneral disorders0/460/431/440/401/530/470/410/462/46
OsteoarthritisMusculoskeletal and connective tissue disorders0/461/430/440/402/530/470/410/462/46
Acute coronary syndromeCardiac disorders0/460/430/441/400/530/470/410/460/46
Atrial fibrillationCardiac disorders0/460/430/441/400/530/471/410/461/46
Coronary artery diseaseCardiac disorders0/460/430/441/400/531/470/410/460/46
PneumoniaInfections and infestations0/460/430/441/400/530/470/410/460/46
Fibula fractureInjury, poisoning and procedural complications0/460/430/441/400/530/471/410/460/46
Tibia fractureInjury, poisoning and procedural complications0/460/430/441/400/530/471/410/460/46
Most frequent other events
Showing 10 of 98
Most frequent other events
EventPlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mg
Upper respiratory tract infectionInfections and infestations11/4615/4310/448/4013/5316/478/4118/4614/46
ArthralgiaMusculoskeletal and connective tissue disorders14/467/4313/449/4012/5311/4710/4112/468/46
Back painMusculoskeletal and connective tissue disorders6/468/4313/445/4010/538/4710/419/467/46
Pain in extremityMusculoskeletal and connective tissue disorders8/466/436/447/4011/537/475/4113/467/46
NasopharyngitisInfections and infestations7/4611/439/444/404/5311/4711/4110/466/46
DyspepsiaGastrointestinal disorders3/465/435/441/4012/536/476/414/4612/46
BronchitisInfections and infestations5/462/431/4410/404/533/471/415/464/46
HypertensionVascular disorders2/464/438/445/4012/535/4710/414/465/46
Influenza like illnessGeneral disorders5/464/434/443/4010/5311/476/413/467/46
NauseaGastrointestinal disorders2/463/436/446/406/535/473/419/4610/46

Baseline characteristics

Age Continuous
Age Continuous(Years)PlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mgTotal
Mean63.7 ± 9.162.8 ± 8.662.3 ± 661.2 ± 8.561.4 ± 8.163.1 ± 8.164.9 ± 8.260.5 ± 7.862.8 ± 8.262.5 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mgTotal
Female464444415447424747412
Male0000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDenosumab 6 mg Q3MDenosumab 14 mg Q3MDenosumab 30 mg Q3MDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MDenosumab 210 mg Q6MAlendronate 70 mgTotal
White or Caucasian373342364939374240355
Black or African American01121130312
Hispanic or Latino88133525439
Asian1100020004
Japanese0000100001
American Indian or Alaska Native0100000001
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B, Libanati C. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom. 2008 Jul-Sep;11(3):351-9. doi: 10.1016/j.jocd.2008.04.001. Epub 2008 May 20. PubMed 18495508 ↗
  • Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA; AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007 Dec;22(12):1832-41. doi: 10.1359/jbmr.070809. PubMed 17708711 ↗
  • McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006 Feb 23;354(8):821-31. doi: 10.1056/NEJMoa044459. PubMed 16495394 ↗
  • Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008 Aug;43(2):222-229. doi: 10.1016/j.bone.2008.04.007. Epub 2008 Apr 26. PubMed 18539106 ↗
  • Peterson MC, Riggs MM. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone. 2010 Jan;46(1):49-63. doi: 10.1016/j.bone.2009.08.053. Epub 2009 Sep 2. PubMed 19732857 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002, a primary completion of Apr 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 3 years 3 months after primary completion. A results delay was requested in Nov 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2002
First posted
Aug 7, 2002
Start
May 2002
Primary completionActual
Apr 2007
CompletionActual
Jun 2007
Results delay requested
Nov 23, 2009
Results first posted
Jul 28, 2010
Last update
Sep 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00043186
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 7, 2002
Start date
May 2002
Primary completion
Apr 2007
Completion
Jun 2007
Results posted
Jul 28, 2010
Last update
Sep 18, 2013

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion